Akebia Therapeutics chief commercial officer Nicholas Grund resigns effective Nov. 6
AKBA•Akebia Therapeutics said Senior Vice President and Chief Commercial Officer Nicholas Grund resigned for personal reasons, effective Nov. 6, 2026. He will provide consulting and advisory services through April 30, 2027.
1. Departure and consulting
Nicholas Grund resigned from Akebia Therapeutics for personal reasons, effective Nov. 6, 2026. He is set to provide consulting and advisory services to the company from that date through April 30, 2027; the arrangement allows early termination with advance written notice.
